Transforming Digital Pathology & AI: The Path Forward

24th May 2022 - Royal College of Physicians of Edinburgh, Scotland

Our expert speaker panel included:

Event overview

Technological advances and the increased focus on precision medicine have recently paved the way for the development of digital pathology-based approaches for quantitative pathologic assessments, namely whole slide imaging and artificial intelligence (AI)–based solutions, allowing us to explore and extract information beyond human visual perception.

However, there are several difficulties encountered in the practical use of AI in clinical diagnosis. These include the lack of sufficient annotated data for the development and validation of AI systems, the explainability of black box AI models and the difficulty in defining the ground truth data for training and validation. All of these together present significant challenges in the development and clinical translation of AI methods in the practice of pathology.

This extremely popular in-person event provided a platform to discuss the above challenges and provide attendees an opportunity to exchange expertise, experiences and actionable information through real time discussions.

Each attendee received:

  • Case studies and presentations from the experts on applications of AI in digital pathology
  • CPD Points
  • Live interaction with senior speakers
  • Panel discussions
  • Exhibition
  • Agenda geared towards networking and close collaboration
  • 1-2-1 Partnering Meetings
  • Keynote across a sit down breakfast
  • Hands-on product/software demos from the industry’s leading tech providers
  • Evening drinks reception and sit down, 3 course Gala Dinner!

Session Moderator:

Some of our expert speaker panel includes:

Professor David Snead

Consultant Pathologist, University Hospitals Coventry and Warwickshire, Professor of Pathology Practice at the University of Warwick and Founding director, PathLAKE

Dr. Jennifer Hay

Laboratory Manager, Glasgow Tissue Research Facility, Scotland, UK

Dr. Gareth Bryson

Consultant Pathologist and Clinical Lead for Technology, NHS Greater Glasgow and Clyde, Honorary Clinical Associate Professor, University of Glasgow, Scotland, UK

Dr. Yasmine Makhlouf

Data Scientist, AI team of Tissue Hybridisation and Digital Pathology in the Precision Medicine Centre of Excellence at Queen’s University Belfast

Senior Representative

Aiforia

Jan Lukas Robertus MD, PhD

Consultant Histopathologist,
Associate Clinical Chief Information Officer, Royal Brompton and Harefield Hospitals, Guy’s and St Thomas’ NHS Foundation Trust UK

Muhammad Aslam

Consultant Pathologist and
Clinical Director
North Wales Managed
Clinical Support Services
Chair Histopath Standing
Specialist Advisory Group
Betsi Cadwaladr, University
Health Board

Emad A Rakha

Professor of Breast Pathology and Consultant.
School of Medicine, University of Nottingham and Department of Cellular Pathology, Nottingham University Hospitals NHS Trust

Technology Partners & Exhibitors:

Aiforia equips pathologists and scientists in preclinical, academic, and clinical labs with the most powerful deep learning artificial intelligence and cloud-based technology to increase the speed, accuracy, and consistency of analyzing large and complex medical images across a variety of fields from oncology to neuroscience.

Aiforia is composed of an ideal mix of scientists experienced in a variety of medical areas from pathology to cancer diagnostics, software developers who collectively hold over 100 years’ experience in artificial intelligence, and a business team with backgrounds in the pharmaceutical and biotechnology industries.

Hospital Services Limited (HSL) is a specialist distributor of medical and surgical equipment, consumable products and healthcare IT solutions servicing public and private hospitals across the UK and Ireland.

Based in the market and at offices in East Midlands, Belfast, and Dublin , HSL is one of the largest privately-owned distributors supplying the health sector. In addition to supplying market leading technologies and solutions, HSL’s team provides on-going technical and clinical support to the end-user of its products. The company’s emphasis on innovation and embedded relationships with healthcare professionals is rooted in understanding healthcare professionals’ needs and challenges faced in the healthcare setting.

Barco is a global technology leader that develops networked visualization solutions for the entertainment, enterprise and healthcare markets. Our solutions help people to enjoy compelling entertainment experiences; they foster knowledge sharing and smart decision-making in organizations and help hospitals provide their patients with the best possible healthcare.

Diagnexia is an online clinical pathology department that provides on-demand access to remote subspecialty pathologists for primary diagnostics and secondary consult services, supporting the achievement of turnaround time goals and delivery of the highest quality of patient care.

Visiopharm® is a world leader in AI-driven precision pathology software.

Visiopharm’s pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in academic institutions, biopharmaceutical industry, and diagnostic centers. Our AI- based image analysis and tissue mining tools support research and drug development research worldwide, while CE-IVD APPs support primary diagnostics. With the most advanced and sophisticated artificial intelligence and deep learning, Visiopharm delivers tissue data mining tools, precision results, and workflows.

Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 900 licenses and countless users in more than 40 countries. The company headquarters are in Denmark’s Medicon Valley, with offices in Sweden, England, Germany, and the United States.

AIRA Matrix provides Artificial Intelligence solutions for Life Sciences applications. Our products and services improve efficiency, diagnostic accuracy, and turnaround times in pathology laboratory workflows. Our diagnostic, prognostic, and predictive solutions for cancer care aid disease stratification and enable management protocols tailored to improve treatment outcomes. Our clients and partners include leading hospitals, pharmaceutical companies, CROs, and research labs around the world.

Since 2016, Ibex has led the way in AI-powered diagnostics for pathology. We set out to transform pathology by ensuring that every patient can receive an accurate, timely and personalized cancer diagnosis.

Today, we are the most widely-deployed artificial intelligence platform in pathology. Developed by pathologists for pathologists, our solutions serve the world’s leading physicians, healthcare organizations and diagnostic providers.

Every day, we have the privilege of touching the lives of patients worldwide. We raise physician confidence, streamline diagnostic workflows, help clinicians provide more personalized diagnosis and, most importantly, enable better clinical outcomes.

Established in 1947 FFEI has an impressive reputation for developing innovative and award winning digital inkjet and life science solutions – from concept to delivery.  Most importantly, FFEI works closely with customers to ensure their market knowledge is transformed into the digital imaging system they need to meet their bespoke requirements.

Led by a team of experts in the fields of life sciences, oncology, pathology, technology, machine learning, and healthcare, Paige strives to transform cancer diagnostics. We make it possible not only to provide additional information from digital slides to help pathologists perform their diagnostic work efficiently and confidently, but also to go beyond by extracting novel insights from digital slides that can’t be seen by the naked eye. These unique tissue signatures have the potential to help guide treatment decisions and enable the development of novel biomarkers from tissues for diagnostic, pharmaceutical and life sciences companies.

Ultivue provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Our proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research.

iCAIRD is a world-class centre of excellence focusing on the application of artificial intelligence within clinical practice. iCAIRD allows clinicians, health planners and industry to work together, enabling research-active clinicians to collaborate with innovative SMEs to better inform clinical questions, and ultimately to solve healthcare challenges more quickly and efficiently.

iCAIRD brings together a pan-Scotland collaboration of over 30 partners from across industry, the NHS, and academia. Industry leadership is being provided by Canon Medical Research Europe in radiology and Philips in digital pathology. iCAIRD research groups in Glasgow, Edinburgh, St.Andrews & Aberdeen work closely with NHS Greater Glasgow & Clyde, NHS Grampian & NHS Lothian.

Media & Programme Partners:

Live Events

Take a look at our live events below…

No data was found

Join our mailing list

Sign up to our email newsletter for all the latest news, opportunities and upcoming events.

Scroll to Top
× WhatsApp